European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antithrombotic agents - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. (see section 4.4 for haemodynamically unstable pe patients.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. (see section 4.4 for haemodynamically unstable pe patients).adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. (see section 4.4 for haemodynamically unstable pe patients.)paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. (see section 4.4 for haemodynamically unstable pe patients.)paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - English - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.-------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. 

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - bivalirudin, quantity: 250 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - bivalirudin sxp is indicated for use as an anticoagulant: ,? in the treatment of patients with moderate to high risk acute coronary syndromes (acs) (unstable angina/non-st segment elevation myocardial infarction (ua/nstemi) who are undergoing early invasive management, and ,? in patients undergoing percutaneous coronary intervention (pci). ,bivalirudin sxp is intended for use with aspirin. ,a p2y12 antagonist (eg clopidogrel or ticlopidine) may be used in addition to aspirin.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - clopidogrel hydrobromide monohydrate - film coated tablet - 75 milligram - platelet aggregation inhibitors excl. heparin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - ibuprofen; pseudoephedrine hydrochloride - film-coated tablet - 200/30 milligram(s) - other cold preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - ibuprofen; pseudoephedrine hydrochloride - film-coated tablet - 200 mg/30 milligram(s) - other cold preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

splendris pharmaceuticals gmbh - clopidogrel hydrogen sulphate - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - escitalopram oxalate - film-coated tablet - escitalopram

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - escitalopram oxalate - film-coated tablet - escitalopram

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - escitalopram oxalate - film-coated tablet - escitalopram